NPPA slashes cancer drug MRPs by up to 93%; Thiotepa cut by ₹72,921 | Mint
The drug pricing regulator has slashed retail prices of 543 formulations across 137 non-scheduled cancer medicines, with some cuts exceeding 90% under a trade margin rationalisation framework.
Ähnliche Seiten
Cancer drug prices slashed by up to 90%; new rates effective from November 9 - The Tribune